Treatment Approaches for Atypical CIDP.

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Chronic inflammatory demyelinating polyneuropathy (CIDP) presents with diverse variants.
• These variants often exhibit distinct clinical, pathological, and electrophysiological features.
• Atypical CIDP variants frequently show limited response to conventional immunosuppressive agents effective in typical CIDP.

Purpose of the Study:

• To review and summarize current treatment approaches for various atypical CIDP variants.
• To evaluate the efficacy of different therapeutic strategies based on existing evidence.
• To identify optimal management for CIDP variants with suboptimal responses to standard therapies.

Main Methods:

• Review of existing literature and clinical data on CIDP variants.
• Analysis of treatment responses for specific subtypes like DADS, MADSAM, pure sensory CIDP, pure motor CIDP, and focal CIDP.
• Evaluation of evidence supporting immunomodulatory therapy (IMT) and specific agents like rituximab.

Main Results:

• Distal acquired demyelinating symmetric polyneuropathy (DADS) with paraproteinemia and anti-MAG antibodies (DADS-M) responds suboptimally to standard therapy but favorably to rituximab.
• Multifocal acquired demyelinating sensory and motor neuropathy (MADSAM) shows a less favorable response to conventional IMT compared to typical CIDP.
• Pure sensory CIDP and chronic inflammatory sensory polyradiculoneuropathy (CISP) respond to first-line IMT (especially IVIG) but require maintenance therapy.
• Pure motor CIDP and focal CIDP variants also respond to first-line IMT, with IVIG being a primary option.
• Overall, atypical CIDP variants show suboptimal responses to conventional IMT but benefit from agents like rituximab, particularly in refractory cases and CIDP with IgG4 antibodies.

Conclusions:

• Atypical CIDP variants necessitate tailored treatment strategies beyond standard CIDP management.
• First-line immunomodulatory therapies, including IVIG, are beneficial but often insufficient for long-term control.
• Rituximab demonstrates significant efficacy in specific CIDP variants like DADS-M and IgG4-related CIDP, and in cases refractory to conventional treatments.